This inventor holds 2 USPTO granted patents and 10 published patent applications and 2 EPO patents. Top assignee: Ventus Therapeutics U.s., Inc.. Active years: 2022-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2025
Title: Innovations of Alexandre Côté in Pyridazine Compounds
Introduction
Alexandre Côté is an accomplished inventor based in Laval, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific proteins involved in various diseases.
Latest Patents
Côté holds a patent for Pyridazine compounds that inhibit NLRP3. This patent is particularly relevant for its potential applications in treating diseases and disorders associated with the NLRP3 protein. The formula outlined in his patent provides a foundation for further research and development in this area.
Career Highlights
Côté's career is marked by his innovative approach to drug development. His work at Ventus Therapeutics U.S., Inc. has positioned him as a key player in the pharmaceutical industry. With a focus on creating effective inhibitors, he has contributed to advancements that could lead to new treatment options for patients.
Collaborations
Côté collaborates with talented professionals in his field, including Stéphane Dorich and Jason Burch. These partnerships enhance the research and development process, fostering an environment of innovation and creativity.
Conclusion
In summary, Alexandre Côté's work in developing Pyridazine compounds represents a significant advancement in the treatment of diseases linked to the NLRP3 protein. His contributions to the pharmaceutical industry are noteworthy and hold promise for future medical breakthroughs.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile